JP2004531484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531484A5 JP2004531484A5 JP2002565984A JP2002565984A JP2004531484A5 JP 2004531484 A5 JP2004531484 A5 JP 2004531484A5 JP 2002565984 A JP2002565984 A JP 2002565984A JP 2002565984 A JP2002565984 A JP 2002565984A JP 2004531484 A5 JP2004531484 A5 JP 2004531484A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- substituted
- pyridyl
- phenyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 —OR 3 Chemical group 0.000 claims 640
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 136
- 125000001424 substituent group Chemical group 0.000 claims 116
- 150000001875 compounds Chemical class 0.000 claims 107
- 125000005843 halogen group Chemical group 0.000 claims 90
- 125000000623 heterocyclic group Chemical group 0.000 claims 89
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 65
- 125000001072 heteroaryl group Chemical group 0.000 claims 49
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims 46
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 45
- 125000005956 isoquinolyl group Chemical group 0.000 claims 40
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 39
- 125000004076 pyridyl group Chemical group 0.000 claims 38
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 37
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 34
- 229910052799 carbon Inorganic materials 0.000 claims 33
- 125000001041 indolyl group Chemical group 0.000 claims 33
- 125000005493 quinolyl group Chemical group 0.000 claims 33
- 125000001188 haloalkyl group Chemical group 0.000 claims 32
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 125000002098 pyridazinyl group Chemical group 0.000 claims 32
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 32
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 30
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 28
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 28
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 27
- 125000004043 oxo group Chemical group O=* 0.000 claims 27
- 125000001544 thienyl group Chemical group 0.000 claims 27
- 125000002883 imidazolyl group Chemical group 0.000 claims 26
- 125000003226 pyrazolyl group Chemical group 0.000 claims 26
- 125000001624 naphthyl group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000003107 substituted aryl group Chemical group 0.000 claims 23
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 23
- 125000005466 alkylenyl group Chemical group 0.000 claims 22
- 125000002541 furyl group Chemical group 0.000 claims 22
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 16
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 15
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 14
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 14
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 14
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 14
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 14
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 13
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 13
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 11
- 125000000335 thiazolyl group Chemical group 0.000 claims 11
- 125000001425 triazolyl group Chemical group 0.000 claims 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 7
- 229960003966 nicotinamide Drugs 0.000 claims 7
- 239000011570 nicotinamide Substances 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 6
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 6
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000005469 ethylenyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 6
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 6
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 5
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 5
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 5
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 4
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 4
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 claims 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 4
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- WGJHGKUXAFXEQX-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 WGJHGKUXAFXEQX-UHFFFAOYSA-N 0.000 claims 2
- LYFDVPOSCCMOBX-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide hydrochloride Chemical compound Cl.N1=CC=C(C=C1)CNC1=C(C(=O)N)C=CC=N1 LYFDVPOSCCMOBX-UHFFFAOYSA-N 0.000 claims 2
- CUMQTVPKMVNWHU-UHFFFAOYSA-N 2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=CC=N1 CUMQTVPKMVNWHU-UHFFFAOYSA-N 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- RGMHIWWBTDCTFP-UHFFFAOYSA-N 6-chloro-n-(3,4-dichlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(Cl)=CC=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 RGMHIWWBTDCTFP-UHFFFAOYSA-N 0.000 claims 2
- VZOQOTFQDURGAQ-UHFFFAOYSA-N 6-chloro-n-(3-fluorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound FC1=CC=CC(NC(=O)C=2C(=NC(Cl)=CC=2)NCC=2C=CN=CC=2)=C1 VZOQOTFQDURGAQ-UHFFFAOYSA-N 0.000 claims 2
- DJBWOZWLNICJDD-UHFFFAOYSA-N 6-chloro-n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=C(Cl)N=C1NCC1=CC=NC=C1 DJBWOZWLNICJDD-UHFFFAOYSA-N 0.000 claims 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 2
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims 2
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- XOGXKXFCJXASMM-UHFFFAOYSA-N n-(2-cyclohexylethyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NCCC1CCCCC1 XOGXKXFCJXASMM-UHFFFAOYSA-N 0.000 claims 2
- OYJAYZAEARMXTP-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 OYJAYZAEARMXTP-UHFFFAOYSA-N 0.000 claims 2
- ZLLZCFGMCYCOBQ-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-(quinolin-6-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(N=CC=C2)C2=C1 ZLLZCFGMCYCOBQ-UHFFFAOYSA-N 0.000 claims 2
- FUBGESDOASSFLE-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6-methyl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(C)=CC=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 FUBGESDOASSFLE-UHFFFAOYSA-N 0.000 claims 2
- BYYGTPFQKSTOIQ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound ClC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 BYYGTPFQKSTOIQ-UHFFFAOYSA-N 0.000 claims 2
- FXKUDTQNLVDDPM-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(F)C(C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 FXKUDTQNLVDDPM-UHFFFAOYSA-N 0.000 claims 2
- PWLWXRCABALOJM-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-6-methyl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(C)=CC=C1C(=O)NC1=CC=C(C)C(F)=C1 PWLWXRCABALOJM-UHFFFAOYSA-N 0.000 claims 2
- GATIRXMKKFCDFM-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2ON=C(C=2)C(C)(C)C)=CC=N1 GATIRXMKKFCDFM-UHFFFAOYSA-N 0.000 claims 2
- CQJYAKDFNABDNR-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(2-pyridin-4-ylethylamino)-5-thiophen-3-ylpyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC(C2=CSC=C2)=CN=C1NCCC1=CC=NC=C1 CQJYAKDFNABDNR-UHFFFAOYSA-N 0.000 claims 2
- NOSWLVYNWMYEPM-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 NOSWLVYNWMYEPM-UHFFFAOYSA-N 0.000 claims 2
- PUYKJIDZYZMYNZ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(quinolin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC2=CC=CC=C12 PUYKJIDZYZMYNZ-UHFFFAOYSA-N 0.000 claims 2
- HFBFVZHPVWEKEW-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(quinolin-5-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=CC2=NC=CC=C12 HFBFVZHPVWEKEW-UHFFFAOYSA-N 0.000 claims 2
- PAKQOXUFEOQJMO-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylamino)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=NC=CC=C1NCC1=CC=NC=C1 PAKQOXUFEOQJMO-UHFFFAOYSA-N 0.000 claims 2
- WDJDWILIGYPHAK-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylamino)pyridine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=NC=C1NCC1=CC=NC=C1 WDJDWILIGYPHAK-UHFFFAOYSA-N 0.000 claims 2
- LXJWXTCBXDALRB-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=C(NCC=2C=CN=CC=2)C=CS1 LXJWXTCBXDALRB-UHFFFAOYSA-N 0.000 claims 2
- VAYFGMAFEDYANQ-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(quinolin-6-ylmethylamino)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=NC=CC=C1NCC1=CC=C(N=CC=C2)C2=C1 VAYFGMAFEDYANQ-UHFFFAOYSA-N 0.000 claims 2
- DROLXAIBBJVFAX-UHFFFAOYSA-N n-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=C1C(=O)NC=2C=CC(Cl)=CC=2)=CN=C1NCC1=CC=NC=C1 DROLXAIBBJVFAX-UHFFFAOYSA-N 0.000 claims 2
- IUVWAGKDBBJAOZ-UHFFFAOYSA-N n-(4-chlorophenyl)-6-methyl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(C)=CC=C1C(=O)NC1=CC=C(Cl)C=C1 IUVWAGKDBBJAOZ-UHFFFAOYSA-N 0.000 claims 2
- IPXMIRXLYKKBFL-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 IPXMIRXLYKKBFL-UHFFFAOYSA-N 0.000 claims 2
- BDAZNAIKZSBCMI-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 BDAZNAIKZSBCMI-UHFFFAOYSA-N 0.000 claims 2
- KHNJHPHQHJEOJW-UHFFFAOYSA-N n-[3,3-dimethyl-1-(1-methylpiperidin-4-yl)-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C3CCN(C)CC3)(C)C)=CC=2)=C1 KHNJHPHQHJEOJW-UHFFFAOYSA-N 0.000 claims 2
- XRYRSTQEFURRFF-UHFFFAOYSA-N n-phenyl-3-(pyridin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C=CN=CC=2)=C1C(=O)NC1=CC=CC=C1 XRYRSTQEFURRFF-UHFFFAOYSA-N 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 1
- XYOVRYLVCDCUPA-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)-n-[3,3-dimethyl-1-[(1-methylpiperidin-4-yl)methyl]-2h-indol-6-yl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=C4CCOC4=CC=3)=CC=C2C(C)(C)C1 XYOVRYLVCDCUPA-UHFFFAOYSA-N 0.000 claims 1
- YNIVBHYQUVVEDL-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)-n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(OCC2)C2=C1 YNIVBHYQUVVEDL-UHFFFAOYSA-N 0.000 claims 1
- LLTSIWYJZUHBQZ-UHFFFAOYSA-N 2-(2-pyridin-3-ylethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCCC=2C=NC=CC=2)=C1 LLTSIWYJZUHBQZ-UHFFFAOYSA-N 0.000 claims 1
- KBWQJCSCFQLMCD-UHFFFAOYSA-N 2-(pyridin-2-ylmethylamino)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1NCC1=CC=CC=N1 KBWQJCSCFQLMCD-UHFFFAOYSA-N 0.000 claims 1
- YMRSATIJVNCOPK-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-(2,2,4-trimethyl-3h-1,4-benzoxazin-6-yl)pyridine-3-carboxamide Chemical compound C1=C2N(C)CC(C)(C)OC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YMRSATIJVNCOPK-UHFFFAOYSA-N 0.000 claims 1
- COIKPNQSXNEPGS-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 COIKPNQSXNEPGS-UHFFFAOYSA-N 0.000 claims 1
- NJTGDBWQCMIQSD-UHFFFAOYSA-N 2-(pyrimidin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2N=CN=CC=2)=C1 NJTGDBWQCMIQSD-UHFFFAOYSA-N 0.000 claims 1
- QKLUVLMTCUXCEY-UHFFFAOYSA-N 2-(quinolin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1NCC1=CC=NC2=CC=CC=C12 QKLUVLMTCUXCEY-UHFFFAOYSA-N 0.000 claims 1
- LTUPGTYYMNFEJH-UHFFFAOYSA-N 2-(quinolin-6-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C3C=CC=NC3=CC=2)=C1 LTUPGTYYMNFEJH-UHFFFAOYSA-N 0.000 claims 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 claims 1
- HOKUTCLIRMVHQV-UHFFFAOYSA-N 2-[(1-pyridin-2-ylpyrrolidin-3-yl)amino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NC2CN(CC2)C=2N=CC=CC=2)=C1 HOKUTCLIRMVHQV-UHFFFAOYSA-N 0.000 claims 1
- TXTUPLWKPJPKBP-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-(4-propan-2-ylphenyl)pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)C)=C1 TXTUPLWKPJPKBP-UHFFFAOYSA-N 0.000 claims 1
- CERDGDLLQVHYPX-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[3-(piperazin-1-ylmethyl)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(CN3CCNCC3)C=2)C(F)(F)F)=C1 CERDGDLLQVHYPX-UHFFFAOYSA-N 0.000 claims 1
- NYLOKYVJQDJMQZ-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[3-(piperidin-4-ylmethoxy)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3CCNCC3)C=2)C(F)(F)F)=C1 NYLOKYVJQDJMQZ-UHFFFAOYSA-N 0.000 claims 1
- TXOGEIFORPBDHE-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[3-[(1-methylpyrrolidin-2-yl)methoxy]-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3N(CCC3)C)C=2)C(F)(F)F)=C1 TXOGEIFORPBDHE-UHFFFAOYSA-N 0.000 claims 1
- ROPVZFCDWKRFKJ-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C2CCN(C)CC2)=C1 ROPVZFCDWKRFKJ-UHFFFAOYSA-N 0.000 claims 1
- SSCBBNIHQRXPIR-UHFFFAOYSA-N 2-[2-(pyridin-2-ylamino)ethylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCCNC=2N=CC=CC=2)=C1 SSCBBNIHQRXPIR-UHFFFAOYSA-N 0.000 claims 1
- INXYXWVQQJQGIO-UHFFFAOYSA-N 2-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(C(F)(F)F)(C1=CC=C(C=C1)C1=C(C(=O)N)C=CC=N1)F INXYXWVQQJQGIO-UHFFFAOYSA-N 0.000 claims 1
- XYCDDKZBMCXWAK-UHFFFAOYSA-N 2-[[2-(1-benzhydrylazetidin-3-yl)oxypyridin-4-yl]methylamino]-n-(4-tert-butylphenyl)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 XYCDDKZBMCXWAK-UHFFFAOYSA-N 0.000 claims 1
- AHKVAESKNOYUMX-UHFFFAOYSA-N 2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 AHKVAESKNOYUMX-UHFFFAOYSA-N 0.000 claims 1
- XIQXYURANRUOSO-UHFFFAOYSA-N 2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 XIQXYURANRUOSO-UHFFFAOYSA-N 0.000 claims 1
- IEQVZGWSOKYXIG-UHFFFAOYSA-N 2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C(OCCN3CCOCC3)N=CC=2)=C1 IEQVZGWSOKYXIG-UHFFFAOYSA-N 0.000 claims 1
- MAKBQHLZGNZKQT-UHFFFAOYSA-N 2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 MAKBQHLZGNZKQT-UHFFFAOYSA-N 0.000 claims 1
- RCLJTNULOBRPSH-UHFFFAOYSA-N 2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 RCLJTNULOBRPSH-UHFFFAOYSA-N 0.000 claims 1
- PPKHCDXFNAAYJK-UHFFFAOYSA-N 2-[[2-(3-morpholin-4-ylpropoxy)pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCCN2CCOCC2)=C1 PPKHCDXFNAAYJK-UHFFFAOYSA-N 0.000 claims 1
- PHOULOWXCBGHLV-UHFFFAOYSA-N 2-[[2-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2N=C(NCCCN3CCOCC3)N=CC=2)=C1 PHOULOWXCBGHLV-UHFFFAOYSA-N 0.000 claims 1
- QACHNSLVBBEDKH-UHFFFAOYSA-N 2-[[2-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(NCCCN2CCOCC2)=N1 QACHNSLVBBEDKH-UHFFFAOYSA-N 0.000 claims 1
- HZQVYXSXHOVAOQ-UHFFFAOYSA-N 2-[[2-(azetidin-3-yloxy)pyridin-4-yl]methylamino]-n-(4-tert-butylphenyl)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OC2CNC2)=C1 HZQVYXSXHOVAOQ-UHFFFAOYSA-N 0.000 claims 1
- QWPCFTMDAOHVNP-UHFFFAOYSA-N 2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]-n-[3-(1-methylpiperidin-4-yl)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(C=2)C2CCN(C)CC2)C(F)(F)F)=CC=N1 QWPCFTMDAOHVNP-UHFFFAOYSA-N 0.000 claims 1
- SBTNGLZXVQGGMX-UHFFFAOYSA-N 2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 SBTNGLZXVQGGMX-UHFFFAOYSA-N 0.000 claims 1
- MNTZQGOXCKQRJL-UHFFFAOYSA-N 2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 MNTZQGOXCKQRJL-UHFFFAOYSA-N 0.000 claims 1
- BYRCEWFUMAJVCS-UHFFFAOYSA-N 2-[[2-[(1-methylpyrrolidin-2-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound CN1CCCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 BYRCEWFUMAJVCS-UHFFFAOYSA-N 0.000 claims 1
- PBGIJPWVDAQQCY-UHFFFAOYSA-N 2-[[2-[(1-propan-2-ylazetidin-3-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1N(C(C)C)CC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 PBGIJPWVDAQQCY-UHFFFAOYSA-N 0.000 claims 1
- SNBHXHNYLUUFIL-UHFFFAOYSA-N 2-[[2-[2-[2-(dimethylamino)ethoxy]ethoxy]pyridin-4-yl]methylamino]-6-fluoro-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OCCOCCN(C)C)=CC(CNC=2C(=CC=C(F)N=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 SNBHXHNYLUUFIL-UHFFFAOYSA-N 0.000 claims 1
- LBNUPUAGNWOLIF-UHFFFAOYSA-N 2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=CC=N1 LBNUPUAGNWOLIF-UHFFFAOYSA-N 0.000 claims 1
- LJIIHWGLUXQUAG-UHFFFAOYSA-N 2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 LJIIHWGLUXQUAG-UHFFFAOYSA-N 0.000 claims 1
- RWGCMIAKFYQOLL-UHFFFAOYSA-N 2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 RWGCMIAKFYQOLL-UHFFFAOYSA-N 0.000 claims 1
- AGSDASDGMNDAIE-UHFFFAOYSA-N 2-aminopyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(N)=C1 AGSDASDGMNDAIE-UHFFFAOYSA-N 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- GPFCIUJVYMETBL-UHFFFAOYSA-N 5-bromo-n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC(Br)=CN=C1NCC1=CC=NC=C1 GPFCIUJVYMETBL-UHFFFAOYSA-N 0.000 claims 1
- GKJDPAHTZVRQEZ-UHFFFAOYSA-N 5-fluoro-n-(4-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC(F)=CN=C1NCC1=CC=NC=C1 GKJDPAHTZVRQEZ-UHFFFAOYSA-N 0.000 claims 1
- ONNJAGRQSIAWEJ-UHFFFAOYSA-N 6-chloro-5-fluoro-n-(4-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC(F)=C(Cl)N=C1NCC1=CC=NC=C1 ONNJAGRQSIAWEJ-UHFFFAOYSA-N 0.000 claims 1
- IXHFATWAZQPRJW-UHFFFAOYSA-N 6-chloro-n-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound ClC1=CC=CC(NC(=O)C=2C(=NC(Cl)=CC=2)NCC=2C=CN=CC=2)=C1 IXHFATWAZQPRJW-UHFFFAOYSA-N 0.000 claims 1
- DVIUDAIRNHXRFA-UHFFFAOYSA-N 6-fluoro-2-(pyridin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(F)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 DVIUDAIRNHXRFA-UHFFFAOYSA-N 0.000 claims 1
- DHVHQZSWWJWAHU-UHFFFAOYSA-N 6-fluoro-n-(4-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=C(F)N=C1NCC1=CC=NC=C1 DHVHQZSWWJWAHU-UHFFFAOYSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- URBJDFIKIVBIHQ-UHFFFAOYSA-N CCl.N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C(=O)O)C=C1 Chemical compound CCl.N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C(=O)O)C=C1 URBJDFIKIVBIHQ-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- AJHJQHFJVJEBLL-UHFFFAOYSA-N Cl.C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 Chemical compound Cl.C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 AJHJQHFJVJEBLL-UHFFFAOYSA-N 0.000 claims 1
- QHHOBCMFMNGWJO-UHFFFAOYSA-N Cl.C=1C=CC2=CC=CN=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1.FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 Chemical compound Cl.C=1C=CC2=CC=CN=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1.FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 QHHOBCMFMNGWJO-UHFFFAOYSA-N 0.000 claims 1
- FRSHTXKRAWJWLT-UHFFFAOYSA-N Cl.C=1C=CC=2CCCCC=2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 Chemical compound Cl.C=1C=CC=2CCCCC=2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 FRSHTXKRAWJWLT-UHFFFAOYSA-N 0.000 claims 1
- XJWRDKINUDCQET-UHFFFAOYSA-N Cl.FC1=C(F)C(F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 Chemical compound Cl.FC1=C(F)C(F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 XJWRDKINUDCQET-UHFFFAOYSA-N 0.000 claims 1
- CPJDCDFSDJDXBE-UHFFFAOYSA-N N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)OCCC1NCCCC1 Chemical compound N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)OCCC1NCCCC1 CPJDCDFSDJDXBE-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000003939 benzylamines Chemical class 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims 1
- 210000002816 gill Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- SMYFIVSTUSZAQE-UHFFFAOYSA-N n-(1-acetyl-2,3-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CCC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 SMYFIVSTUSZAQE-UHFFFAOYSA-N 0.000 claims 1
- JYMFZDXRKLPERK-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2OCCC2=CC(CNC2=NC=CC=C2C(=O)NC2=CC=C3C(C)(C)CN(C3=C2)C(=O)C)=C1 JYMFZDXRKLPERK-UHFFFAOYSA-N 0.000 claims 1
- PCBJMPHFCPGDOA-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=C1 PCBJMPHFCPGDOA-UHFFFAOYSA-N 0.000 claims 1
- YXZVNJFQHDYYMB-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=CC=N1 YXZVNJFQHDYYMB-UHFFFAOYSA-N 0.000 claims 1
- UDPWIPQPPRGTBJ-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CN=C1NCC(C=1)=CC=NC=1OCCN1CCOCC1 UDPWIPQPPRGTBJ-UHFFFAOYSA-N 0.000 claims 1
- NCBQRLJNOYWQKM-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-(3-morpholin-4-ylpropylamino)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CN=C1NCC(C=1)=CC=NC=1NCCCN1CCOCC1 NCBQRLJNOYWQKM-UHFFFAOYSA-N 0.000 claims 1
- ZKHWMCVUDATADE-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=CC=N1 ZKHWMCVUDATADE-UHFFFAOYSA-N 0.000 claims 1
- VVCFSPYQWQPPPO-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=CC=N1 VVCFSPYQWQPPPO-UHFFFAOYSA-N 0.000 claims 1
- HPYHOOUXTPVSMT-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyrimidin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCNC1=NC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=N1 HPYHOOUXTPVSMT-UHFFFAOYSA-N 0.000 claims 1
- OTNXTXUZILTZNA-UHFFFAOYSA-N n-(1-bromoisoquinolin-3-yl)-6-fluoro-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound N=1C(F)=CC=C(C(=O)NC=2N=C(Br)C3=CC=CC=C3C=2)C=1NCC1=CC=NC=C1 OTNXTXUZILTZNA-UHFFFAOYSA-N 0.000 claims 1
- VJDQMBCYBAQIMT-UHFFFAOYSA-N n-(1h-indol-5-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2NC=CC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 VJDQMBCYBAQIMT-UHFFFAOYSA-N 0.000 claims 1
- RIPLKGXLISXLCH-UHFFFAOYSA-N n-(1h-indol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C=CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RIPLKGXLISXLCH-UHFFFAOYSA-N 0.000 claims 1
- IHNKWRULZICRCP-UHFFFAOYSA-N n-(1h-indol-7-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CC=2C=CNC=2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 IHNKWRULZICRCP-UHFFFAOYSA-N 0.000 claims 1
- YWTDZDOTXLSQIL-UHFFFAOYSA-N n-(2,2-dimethyl-3,4-dihydro-1,4-benzoxazin-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2OC(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YWTDZDOTXLSQIL-UHFFFAOYSA-N 0.000 claims 1
- XIQMSHOOZLOEHV-UHFFFAOYSA-N n-(2,2-dimethyl-3-oxo-4h-1,4-benzoxazin-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2NC(=O)C(C)(C)OC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 XIQMSHOOZLOEHV-UHFFFAOYSA-N 0.000 claims 1
- BUDCPIVSSBWUMO-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1C2=CC=CC=C2CC1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 BUDCPIVSSBWUMO-UHFFFAOYSA-N 0.000 claims 1
- OEZQZEQUTLOKTO-UHFFFAOYSA-N n-(2,3-dihydro-1h-indol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2CCNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 OEZQZEQUTLOKTO-UHFFFAOYSA-N 0.000 claims 1
- HCYMVVRCWLJAEZ-UHFFFAOYSA-N n-(2-phenoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC1=CC=CC=C1OC1=CC=CC=C1 HCYMVVRCWLJAEZ-UHFFFAOYSA-N 0.000 claims 1
- KYJBFKIOZUXHFX-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=C1 KYJBFKIOZUXHFX-UHFFFAOYSA-N 0.000 claims 1
- VYBOPFMRQIOZEG-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 VYBOPFMRQIOZEG-UHFFFAOYSA-N 0.000 claims 1
- KYBXRQHAJWDMGN-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC(C=1)=CC=NC=1OCCN1CCOCC1 KYBXRQHAJWDMGN-UHFFFAOYSA-N 0.000 claims 1
- HSKJFFKAHWCESH-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-(2-morpholin-4-ylpropoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C=1C(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=NC=1OCC(C)N1CCOCC1 HSKJFFKAHWCESH-UHFFFAOYSA-N 0.000 claims 1
- RQNIKVDISSISFT-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 RQNIKVDISSISFT-UHFFFAOYSA-N 0.000 claims 1
- BIWVHHRPMXPYFE-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 BIWVHHRPMXPYFE-UHFFFAOYSA-N 0.000 claims 1
- CJOSBJQFCCDYLS-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyrimidin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCNC1=NC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=N1 CJOSBJQFCCDYLS-UHFFFAOYSA-N 0.000 claims 1
- LKFJIAOIVGBNQD-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 LKFJIAOIVGBNQD-UHFFFAOYSA-N 0.000 claims 1
- RYUOHJFJSRQTNX-UHFFFAOYSA-N n-(3,3-dimethyl-1-piperidin-4-yl-2h-indol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C12=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)CN1C1CCNCC1 RYUOHJFJSRQTNX-UHFFFAOYSA-N 0.000 claims 1
- OBVVHNKKESTIQE-UHFFFAOYSA-N n-(3,3-dimethyl-1-piperidin-4-yl-2h-indol-6-yl)-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C3CCNCC3)(C)C)=CC=2)=C1 OBVVHNKKESTIQE-UHFFFAOYSA-N 0.000 claims 1
- BXOKJVYFRVHMLH-UHFFFAOYSA-N n-(3,3-dimethyl-2h-1-benzofuran-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)COC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 BXOKJVYFRVHMLH-UHFFFAOYSA-N 0.000 claims 1
- FCFABUOVTFFWOG-UHFFFAOYSA-N n-(3,3-dimethyl-2h-1-benzofuran-6-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CO3)(C)C)=CC=2)=CC=N1 FCFABUOVTFFWOG-UHFFFAOYSA-N 0.000 claims 1
- YRFCQBDQLMTWNI-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6-(2-morpholin-4-ylethylamino)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)C(C(=N1)NCC=2C=CN=CC=2)=CC=C1NCCN1CCOCC1 YRFCQBDQLMTWNI-UHFFFAOYSA-N 0.000 claims 1
- JVOUUCKMYRZJFZ-UHFFFAOYSA-N n-(3-benzylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=1)=CC=CC=1CC1=CC=CC=C1 JVOUUCKMYRZJFZ-UHFFFAOYSA-N 0.000 claims 1
- ATZPTMHFZCFQEZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(2-pyridin-4-ylethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.ClC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCCC=2C=CN=CC=2)=C1 ATZPTMHFZCFQEZ-UHFFFAOYSA-N 0.000 claims 1
- VPSIZGXQXQGXAD-UHFFFAOYSA-N n-(3-ethylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CCC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 VPSIZGXQXQGXAD-UHFFFAOYSA-N 0.000 claims 1
- FTNXOWIWIXTBKQ-UHFFFAOYSA-N n-(3-hydroxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound OC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 FTNXOWIWIXTBKQ-UHFFFAOYSA-N 0.000 claims 1
- CCXZIUPUBKQLLC-UHFFFAOYSA-N n-(3-phenoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=1)=CC=CC=1OC1=CC=CC=C1 CCXZIUPUBKQLLC-UHFFFAOYSA-N 0.000 claims 1
- MAVHARHYZLDACC-UHFFFAOYSA-N n-(3-phenylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 MAVHARHYZLDACC-UHFFFAOYSA-N 0.000 claims 1
- CDBAIDSAFYSGIZ-UHFFFAOYSA-N n-(3-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 CDBAIDSAFYSGIZ-UHFFFAOYSA-N 0.000 claims 1
- TXGPTKAMEJJTBS-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 TXGPTKAMEJJTBS-UHFFFAOYSA-N 0.000 claims 1
- OLGLAAMYUFFAFR-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-(3-morpholin-4-ylpropoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCCN2CCOCC2)=C1 OLGLAAMYUFFAFR-UHFFFAOYSA-N 0.000 claims 1
- GCZKZEPEZBTEIV-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2ON=C(C=2)C(C)(C)C)=CC=N1 GCZKZEPEZBTEIV-UHFFFAOYSA-N 0.000 claims 1
- ZVUCDXVCCTUQTG-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2ON=C(C=2)C(C)(C)C)=CC=N1 ZVUCDXVCCTUQTG-UHFFFAOYSA-N 0.000 claims 1
- YCCPQXMCCWWZTM-UHFFFAOYSA-N n-(4,4-dimethyl-1-oxo-2,3-dihydroisoquinolin-7-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CNC(=O)C2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YCCPQXMCCWWZTM-UHFFFAOYSA-N 0.000 claims 1
- CPGMAHUWDQEJAL-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 CPGMAHUWDQEJAL-UHFFFAOYSA-N 0.000 claims 1
- HNOKSHCLWZNCCT-UHFFFAOYSA-N n-(4-acetyl-2,2-dimethyl-3h-1,4-benzoxazin-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)OC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HNOKSHCLWZNCCT-UHFFFAOYSA-N 0.000 claims 1
- KYOKWCJDBBJSAE-UHFFFAOYSA-N n-(4-benzylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1CC1=CC=CC=C1 KYOKWCJDBBJSAE-UHFFFAOYSA-N 0.000 claims 1
- IJDXKJUJRKHXLD-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound FC1=CC(Br)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 IJDXKJUJRKHXLD-UHFFFAOYSA-N 0.000 claims 1
- FNIPQUCQBWNRKB-UHFFFAOYSA-N n-(4-butan-2-ylphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)CC)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=CC=CN=C1 FNIPQUCQBWNRKB-UHFFFAOYSA-N 0.000 claims 1
- AEYMCJZBQPIIEM-UHFFFAOYSA-N n-(4-butan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)CC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 AEYMCJZBQPIIEM-UHFFFAOYSA-N 0.000 claims 1
- NGMFUXHADICHSR-UHFFFAOYSA-N n-(4-butylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 NGMFUXHADICHSR-UHFFFAOYSA-N 0.000 claims 1
- HEVSAJPOQSSZLF-UHFFFAOYSA-N n-(4-chloro-3-sulfamoylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 HEVSAJPOQSSZLF-UHFFFAOYSA-N 0.000 claims 1
- BTLFSXOBYLGYAL-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(pyrimidin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=N1 BTLFSXOBYLGYAL-UHFFFAOYSA-N 0.000 claims 1
- LHVHZZPCFAQYLD-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylideneamino)pyridine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=NC=C1N=CC1=CC=NC=C1 LHVHZZPCFAQYLD-UHFFFAOYSA-N 0.000 claims 1
- DKWNJUQHGBDIDC-UHFFFAOYSA-N n-(4-cyanonaphthalen-1-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=C(C#N)C2=CC=CC=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 DKWNJUQHGBDIDC-UHFFFAOYSA-N 0.000 claims 1
- KNNBCOTVZSLLAJ-UHFFFAOYSA-N n-(4-cyclohexylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1CCCCC1 KNNBCOTVZSLLAJ-UHFFFAOYSA-N 0.000 claims 1
- VJSIHVAITVXFNF-UHFFFAOYSA-N n-(4-ethylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 VJSIHVAITVXFNF-UHFFFAOYSA-N 0.000 claims 1
- RLCSOSKPEXBPHZ-UHFFFAOYSA-N n-(4-imidazol-1-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1N1C=CN=C1 RLCSOSKPEXBPHZ-UHFFFAOYSA-N 0.000 claims 1
- WRQFRRBPQKNLRQ-UHFFFAOYSA-N n-(4-iodophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(I)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 WRQFRRBPQKNLRQ-UHFFFAOYSA-N 0.000 claims 1
- QPZGDJJQONYBID-UHFFFAOYSA-N n-(4-phenoxyphenyl)-2-(2-pyridin-2-ylethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCCC=2N=CC=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 QPZGDJJQONYBID-UHFFFAOYSA-N 0.000 claims 1
- NYNCBNDLRMBIKW-UHFFFAOYSA-N n-(4-phenoxyphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCCC=2C=NC=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 NYNCBNDLRMBIKW-UHFFFAOYSA-N 0.000 claims 1
- XRCHIURCFJPJSO-UHFFFAOYSA-N n-(4-phenoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 XRCHIURCFJPJSO-UHFFFAOYSA-N 0.000 claims 1
- OIKVIWBBKQKRPV-UHFFFAOYSA-N n-(4-phenylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1=CC=CC=C1 OIKVIWBBKQKRPV-UHFFFAOYSA-N 0.000 claims 1
- KSAXCVWMNKSCFQ-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=CC=CN=C1 KSAXCVWMNKSCFQ-UHFFFAOYSA-N 0.000 claims 1
- NBAJKMDQEUEQMW-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-2-(pyridin-2-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=CC=N1 NBAJKMDQEUEQMW-UHFFFAOYSA-N 0.000 claims 1
- KNXMJHFNMXPJOO-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-2-[2-(1h-1,2,4-triazol-5-yl)ethylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=NNC=N1 KNXMJHFNMXPJOO-UHFFFAOYSA-N 0.000 claims 1
- UXTVVIABVSUZEU-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-4-(pyridin-4-ylmethylamino)pyrimidine-5-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CN=CN=C1NCC1=CC=NC=C1 UXTVVIABVSUZEU-UHFFFAOYSA-N 0.000 claims 1
- AJUCYOXULSCKSJ-UHFFFAOYSA-N n-(4-propan-2-ylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)C1=CC=NC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 AJUCYOXULSCKSJ-UHFFFAOYSA-N 0.000 claims 1
- INYJVJWHVRXXFY-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 INYJVJWHVRXXFY-UHFFFAOYSA-N 0.000 claims 1
- VPBOSWJGTMJBGG-UHFFFAOYSA-N n-(4-tert-butyl-3-nitrophenyl)-2-(pyridin-2-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C([N+]([O-])=O)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=CC=N1 VPBOSWJGTMJBGG-UHFFFAOYSA-N 0.000 claims 1
- DWCNVTQMIOJUDB-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=CC=CN=C1 DWCNVTQMIOJUDB-UHFFFAOYSA-N 0.000 claims 1
- YAPUZDQPAAAEDA-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YAPUZDQPAAAEDA-UHFFFAOYSA-N 0.000 claims 1
- WJIJHBZARDSRNM-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(pyrimidin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=N1 WJIJHBZARDSRNM-UHFFFAOYSA-N 0.000 claims 1
- YXEALWXWTUTJEV-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(quinolin-6-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(N=CC=C2)C2=C1 YXEALWXWTUTJEV-UHFFFAOYSA-N 0.000 claims 1
- FRCKJEGIERNSJM-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[(2-chloropyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(Cl)=C1 FRCKJEGIERNSJM-UHFFFAOYSA-N 0.000 claims 1
- UVKOLUKOGSATHY-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[(2-ethylpyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(CC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=C1 UVKOLUKOGSATHY-UHFFFAOYSA-N 0.000 claims 1
- KUJJCXJIGPMUSY-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 KUJJCXJIGPMUSY-UHFFFAOYSA-N 0.000 claims 1
- HFZBCBWADXBTKQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-(2-pyrrolidin-1-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCCC2)=C1 HFZBCBWADXBTKQ-UHFFFAOYSA-N 0.000 claims 1
- IPGXYZZDIYSOQV-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[(1-propan-2-ylazetidin-3-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1N(C(C)C)CC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 IPGXYZZDIYSOQV-UHFFFAOYSA-N 0.000 claims 1
- QNKQVIYUJWTRFC-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 QNKQVIYUJWTRFC-UHFFFAOYSA-N 0.000 claims 1
- UEKVMDATIWSDMF-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 UEKVMDATIWSDMF-UHFFFAOYSA-N 0.000 claims 1
- FQBRBMGUWZLWJQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyrimidin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCNC1=NC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=N1 FQBRBMGUWZLWJQ-UHFFFAOYSA-N 0.000 claims 1
- VFCBJNUUGQRNHY-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-[2-(dimethylamino)ethoxy]ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OCCOCCN(C)C)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=C1 VFCBJNUUGQRNHY-UHFFFAOYSA-N 0.000 claims 1
- KNDBVDAEJLUQNW-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 KNDBVDAEJLUQNW-UHFFFAOYSA-N 0.000 claims 1
- CNRDVPVABNSSAW-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[3-(dimethylamino)prop-1-ynyl]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=NC(C#CCN(C)C)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=C1 CNRDVPVABNSSAW-UHFFFAOYSA-N 0.000 claims 1
- UGSVSPULGCMCKT-HSZRJFAPSA-N n-(4-tert-butylphenyl)-2-[[2-[[(2r)-1-methylpyrrolidin-2-yl]methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCC[C@@H]1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 UGSVSPULGCMCKT-HSZRJFAPSA-N 0.000 claims 1
- HZHWQMINUBOGGQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-6-fluoro-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=C(F)N=C1NCC1=CC=NC=C1 HZHWQMINUBOGGQ-UHFFFAOYSA-N 0.000 claims 1
- QJNSCGAVOHNGNE-UHFFFAOYSA-N n-(4-tert-butylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)(C)C1=CC=NC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 QJNSCGAVOHNGNE-UHFFFAOYSA-N 0.000 claims 1
- ORUDYBDQLKABCG-UHFFFAOYSA-N n-(5-phenyl-1h-pyrazol-3-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(NN=1)=CC=1C1=CC=CC=C1 ORUDYBDQLKABCG-UHFFFAOYSA-N 0.000 claims 1
- UWJPGIUSIAQKQE-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 UWJPGIUSIAQKQE-UHFFFAOYSA-N 0.000 claims 1
- LWEQAKJMOKEOET-UHFFFAOYSA-N n-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound S1C(C(C)(C)C)=NN=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 LWEQAKJMOKEOET-UHFFFAOYSA-N 0.000 claims 1
- VKWMLHPKHNARJP-UHFFFAOYSA-N n-(5-tert-butyl-1h-pyrazol-3-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 VKWMLHPKHNARJP-UHFFFAOYSA-N 0.000 claims 1
- URUDDEQMXIFTCS-UHFFFAOYSA-N n-(6-ethylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CCC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 URUDDEQMXIFTCS-UHFFFAOYSA-N 0.000 claims 1
- BIAMLRWIGLAALI-UHFFFAOYSA-N n-(6-propylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CCCC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 BIAMLRWIGLAALI-UHFFFAOYSA-N 0.000 claims 1
- FWVIMMJFCOQNGY-UHFFFAOYSA-N n-[1-(1-methylpiperidin-4-yl)-2,3-dihydroindol-6-yl]-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC(NC(=O)C=3C(=NC=CC=3)NCCC=3C=NC=CC=3)=CC=C2CC1 FWVIMMJFCOQNGY-UHFFFAOYSA-N 0.000 claims 1
- HXTBDNBGKYWDAP-UHFFFAOYSA-N n-[1-(1-methylpiperidin-4-yl)-2,3-dihydroindol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2CC1 HXTBDNBGKYWDAP-UHFFFAOYSA-N 0.000 claims 1
- WVRSGRIXLWUHOD-UHFFFAOYSA-N n-[1-(2-morpholin-4-ylethyl)indol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C12)=CC=C1C=CN2CCN1CCOCC1 WVRSGRIXLWUHOD-UHFFFAOYSA-N 0.000 claims 1
- IBEXLNCTALRTPQ-UHFFFAOYSA-N n-[1-(2-piperidin-2-ylacetyl)-2,3-dihydroindol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CC2=CC=C(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)C=C2N1C(=O)CC1CCCCN1 IBEXLNCTALRTPQ-UHFFFAOYSA-N 0.000 claims 1
- NUOBXRVOEBRLDO-UHFFFAOYSA-N n-[1-(2-piperidin-2-ylethyl)-2,3-dihydroindol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C12)=CC=C1CCN2CCC1CCCCN1 NUOBXRVOEBRLDO-UHFFFAOYSA-N 0.000 claims 1
- KMYYPFXBWZQPDY-UHFFFAOYSA-N n-[1-[2-(dimethylamino)acetyl]-3,3-dimethyl-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(=O)CN(C)C)(C)C)=CC=2)=C1 KMYYPFXBWZQPDY-UHFFFAOYSA-N 0.000 claims 1
- BWGOLYZJXYJGNW-UHFFFAOYSA-N n-[3,3-dimethyl-1-(1-methylpiperidin-4-yl)-2h-indol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)C1 BWGOLYZJXYJGNW-UHFFFAOYSA-N 0.000 claims 1
- RQGSOSPQIFZFSU-UHFFFAOYSA-N n-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3CC3CCNCC3)(C)C)=CC=2)=C1 RQGSOSPQIFZFSU-UHFFFAOYSA-N 0.000 claims 1
- BPZQMIOAOMVLBW-UHFFFAOYSA-N n-[3,3-dimethyl-1-(pyrrolidin-2-ylmethoxy)-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3OCC3NCCC3)(C)C)=CC=2)=C1 BPZQMIOAOMVLBW-UHFFFAOYSA-N 0.000 claims 1
- XVCCSOVZWSRLQQ-UHFFFAOYSA-N n-[3,3-dimethyl-1-[(1-methylpiperidin-4-yl)methyl]-2h-indol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)C1 XVCCSOVZWSRLQQ-UHFFFAOYSA-N 0.000 claims 1
- GZEPKFYLNUJNBH-UHFFFAOYSA-N n-[3,5-bis(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC(C(F)(F)F)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 GZEPKFYLNUJNBH-UHFFFAOYSA-N 0.000 claims 1
- QMKWTBXPMXDUQL-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QMKWTBXPMXDUQL-UHFFFAOYSA-N 0.000 claims 1
- AIZNXAWAECYQQJ-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)oxy-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 AIZNXAWAECYQQJ-UHFFFAOYSA-N 0.000 claims 1
- SBOPANWRTFAKFW-UHFFFAOYSA-N n-[3-(2-piperidin-1-ylethoxy)-4-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(OCCN2CCCCC2)C(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 SBOPANWRTFAKFW-UHFFFAOYSA-N 0.000 claims 1
- RVLBMLRUNIEDRY-UHFFFAOYSA-N n-[3-(3-morpholin-4-ylpropyl)-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=CC=1CCCN1CCOCC1 RVLBMLRUNIEDRY-UHFFFAOYSA-N 0.000 claims 1
- PJPVFLXGPQUPRO-UHFFFAOYSA-N n-[3-(3-piperidin-1-ylpropyl)-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=CC=1CCCN1CCCCC1 PJPVFLXGPQUPRO-UHFFFAOYSA-N 0.000 claims 1
- HBZADFBPIMGDHL-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 HBZADFBPIMGDHL-UHFFFAOYSA-N 0.000 claims 1
- YFQOPDISULLBEX-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)sulfonylphenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 YFQOPDISULLBEX-UHFFFAOYSA-N 0.000 claims 1
- LUQYQPGSUULSRK-UHFFFAOYSA-N n-[3-[(1-methylpiperidin-4-yl)methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F LUQYQPGSUULSRK-UHFFFAOYSA-N 0.000 claims 1
- ZEGOYJVJXXDBHE-UHFFFAOYSA-N n-[3-[(1-methylpiperidin-4-yl)methyl]-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 ZEGOYJVJXXDBHE-UHFFFAOYSA-N 0.000 claims 1
- QCYXPNPXDUIHFC-HXUWFJFHSA-N n-[3-[(2r)-2-hydroxy-3-pyrrolidin-1-ylpropoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C([C@H](O)CN1CCCC1)OC(C(=CC=1)C(F)(F)C(F)(F)F)=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QCYXPNPXDUIHFC-HXUWFJFHSA-N 0.000 claims 1
- QCYXPNPXDUIHFC-FQEVSTJZSA-N n-[3-[(2s)-2-hydroxy-3-pyrrolidin-1-ylpropoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C([C@@H](O)CN1CCCC1)OC(C(=CC=1)C(F)(F)C(F)(F)F)=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QCYXPNPXDUIHFC-FQEVSTJZSA-N 0.000 claims 1
- NVIFFUXBUQMLMT-UHFFFAOYSA-N n-[3-[(4-methylpiperazin-1-yl)methyl]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F NVIFFUXBUQMLMT-UHFFFAOYSA-N 0.000 claims 1
- XZZZSAFQBWVXJP-UHFFFAOYSA-N n-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC(CCCN(C)C)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 XZZZSAFQBWVXJP-UHFFFAOYSA-N 0.000 claims 1
- QNDWXHLAZMTTFF-HXUWFJFHSA-N n-[3-[[(2r)-1-methylpyrrolidin-2-yl]methoxy]-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CN1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 QNDWXHLAZMTTFF-HXUWFJFHSA-N 0.000 claims 1
- YIDKXOVFDQEFSL-UHFFFAOYSA-N n-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(O)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YIDKXOVFDQEFSL-UHFFFAOYSA-N 0.000 claims 1
- HCVSNRUVUNXQAT-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)-3-(2-piperidin-1-ylethoxy)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(OCCN2CCCCC2)C(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HCVSNRUVUNXQAT-UHFFFAOYSA-N 0.000 claims 1
- HHISJRVODGCDMG-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HHISJRVODGCDMG-UHFFFAOYSA-N 0.000 claims 1
- UWMNUWGCYARTQI-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyrimidin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=N1 UWMNUWGCYARTQI-UHFFFAOYSA-N 0.000 claims 1
- MJLGKPIINGGZCM-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-[[2-(2-pyrrolidin-1-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCCC2)=C1 MJLGKPIINGGZCM-UHFFFAOYSA-N 0.000 claims 1
- GZBOQOFJJBPEDE-UHFFFAOYSA-N n-[4-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 GZBOQOFJJBPEDE-UHFFFAOYSA-N 0.000 claims 1
- BGAVPSNOTCFPDW-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCN)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 BGAVPSNOTCFPDW-UHFFFAOYSA-N 0.000 claims 1
- WAIWQTLSROUTRH-UHFFFAOYSA-N n-[4-(2-methyl-4-morpholin-4-ylbutan-2-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)C=CC=1C(C)(C)CCN1CCOCC1 WAIWQTLSROUTRH-UHFFFAOYSA-N 0.000 claims 1
- PPPHMJMGRRTAAT-UHFFFAOYSA-N n-[4-(4-chlorophenoxy)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 PPPHMJMGRRTAAT-UHFFFAOYSA-N 0.000 claims 1
- KFHYBLFWLWUHCQ-UHFFFAOYSA-N n-[4-(4-hydroxybutyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCCCO)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 KFHYBLFWLWUHCQ-UHFFFAOYSA-N 0.000 claims 1
- FJDDTXZRAVOMLY-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]-n-[2-(pyridin-4-ylmethylamino)pyridin-3-yl]formamide Chemical compound C1CN(C)CCN1C1=CC=C(N(C=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)C=C1 FJDDTXZRAVOMLY-UHFFFAOYSA-N 0.000 claims 1
- ILFSTPMMQSOOJD-UHFFFAOYSA-N n-[4-(morpholin-4-ylmethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1CN1CCOCC1 ILFSTPMMQSOOJD-UHFFFAOYSA-N 0.000 claims 1
- UQNZRWDAWGMJBS-UHFFFAOYSA-N n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 UQNZRWDAWGMJBS-UHFFFAOYSA-N 0.000 claims 1
- WVRRCUQDZMAVII-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 WVRRCUQDZMAVII-UHFFFAOYSA-N 0.000 claims 1
- KCMIRJFWDFYISD-UHFFFAOYSA-N n-[4-tert-butyl-3-(3-morpholin-4-ylpropyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(CCCN2CCOCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 KCMIRJFWDFYISD-UHFFFAOYSA-N 0.000 claims 1
- KKGIDEBPBZIJRB-UHFFFAOYSA-N n-[4-tert-butyl-3-(3-piperidin-3-ylpropyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(CCCC2CNCCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 KKGIDEBPBZIJRB-UHFFFAOYSA-N 0.000 claims 1
- OMJQWGGFSXFZOU-UHFFFAOYSA-N n-[4-tert-butyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(CCCN2CCCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 OMJQWGGFSXFZOU-UHFFFAOYSA-N 0.000 claims 1
- KRFYQNQCQUXSBR-UHFFFAOYSA-N n-[4-tert-butyl-3-(4-methylpiperazin-1-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C KRFYQNQCQUXSBR-UHFFFAOYSA-N 0.000 claims 1
- WFFPIRJZLXANMB-UHFFFAOYSA-N n-[4-tert-butyl-3-[(1-methylazetidin-3-yl)methoxy]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1N(C)CC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C WFFPIRJZLXANMB-UHFFFAOYSA-N 0.000 claims 1
- TURDJROVMKFFKH-UHFFFAOYSA-N n-[4-tert-butyl-3-[(1-methylpiperidin-4-yl)methoxy]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C TURDJROVMKFFKH-UHFFFAOYSA-N 0.000 claims 1
- PVAQZNCCTFFIGR-RUDMXATFSA-N n-[4-tert-butyl-3-[(e)-4-pyrrolidin-1-ylbut-1-enyl]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(\C=C\CCN2CCCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 PVAQZNCCTFFIGR-RUDMXATFSA-N 0.000 claims 1
- PHJRTHKWNXYXQC-UHFFFAOYSA-N n-[5-tert-butyl-2-[2-(dimethylamino)ethoxy]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CN(C)CCOC1=CC=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 PHJRTHKWNXYXQC-UHFFFAOYSA-N 0.000 claims 1
- MCUIEWFNWZMXBM-UHFFFAOYSA-N n-isoquinolin-3-yl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C2=CC=CC=C2C=NC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 MCUIEWFNWZMXBM-UHFFFAOYSA-N 0.000 claims 1
- GTIPBHSTZQVIRN-UHFFFAOYSA-N n-naphthalen-1-yl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 GTIPBHSTZQVIRN-UHFFFAOYSA-N 0.000 claims 1
- IIQYLJRHXQVBCP-UHFFFAOYSA-N n-naphthalen-2-yl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=C2C=CC=CC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 IIQYLJRHXQVBCP-UHFFFAOYSA-N 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 150000003141 primary amines Chemical class 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- NIKQRARLBRMZAI-OAQYLSRUSA-N tert-butyl (2r)-2-[[2-(1,1,2,2,2-pentafluoroethyl)-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F NIKQRARLBRMZAI-OAQYLSRUSA-N 0.000 claims 1
- RRFQDYDKMPHLGV-JOCHJYFZSA-N tert-butyl (2r)-2-[[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 RRFQDYDKMPHLGV-JOCHJYFZSA-N 0.000 claims 1
- FEYSNEFIARBXHD-OAQYLSRUSA-N tert-butyl (2r)-2-[[5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-2-(trifluoromethyl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)F FEYSNEFIARBXHD-OAQYLSRUSA-N 0.000 claims 1
- NIKQRARLBRMZAI-NRFANRHFSA-N tert-butyl (2s)-2-[[2-(1,1,2,2,2-pentafluoroethyl)-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F NIKQRARLBRMZAI-NRFANRHFSA-N 0.000 claims 1
- CSQZJFXVJCLZRI-UHFFFAOYSA-N tert-butyl 2-[[2-tert-butyl-4-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1COC(C(=C1)C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 CSQZJFXVJCLZRI-UHFFFAOYSA-N 0.000 claims 1
- ZMLWTDZGAAIZRM-UHFFFAOYSA-N tert-butyl 2-[[5-[[2-(2,3-dihydro-1-benzofuran-6-ylmethylamino)pyridine-3-carbonyl]amino]-2-(1,1,2,2,2-pentafluoroethyl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C3OCCC3=CC=2)=CC=C1C(F)(F)C(F)(F)F ZMLWTDZGAAIZRM-UHFFFAOYSA-N 0.000 claims 1
- QTIBLBJWTGESGG-UHFFFAOYSA-N tert-butyl 2-[[6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]oxymethyl]pyrrolidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3OCC3N(CCC3)C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 QTIBLBJWTGESGG-UHFFFAOYSA-N 0.000 claims 1
- QOOAVFIGIITHMF-UHFFFAOYSA-N tert-butyl 2-amino-3-[3,3-dimethyl-6-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-2h-indol-1-yl]-3-oxopropanoate Chemical compound C1=C2N(C(=O)C(N)C(=O)OC(C)(C)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QOOAVFIGIITHMF-UHFFFAOYSA-N 0.000 claims 1
- MWQSWYRACGHCEW-UHFFFAOYSA-N tert-butyl 2-amino-3-[6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]-3-oxopropanoate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(=O)C(N)C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 MWQSWYRACGHCEW-UHFFFAOYSA-N 0.000 claims 1
- ZCTOUYXFKCXODN-UHFFFAOYSA-N tert-butyl 3-[[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 ZCTOUYXFKCXODN-UHFFFAOYSA-N 0.000 claims 1
- BBGMAEURHQLMTH-UHFFFAOYSA-N tert-butyl 3-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]azetidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3CN(C3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 BBGMAEURHQLMTH-UHFFFAOYSA-N 0.000 claims 1
- VWOHUDYCECXLCP-UHFFFAOYSA-N tert-butyl 4-[2-[2-tert-butyl-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenyl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C VWOHUDYCECXLCP-UHFFFAOYSA-N 0.000 claims 1
- VTGVDQWJMAIIQY-UHFFFAOYSA-N tert-butyl 4-[3-[[2-(2-pyridin-4-ylethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC(NC(=O)C=2C(=NC=CC=2)NCCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 VTGVDQWJMAIIQY-UHFFFAOYSA-N 0.000 claims 1
- BMGWASDKBNKGEI-UHFFFAOYSA-N tert-butyl 4-[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 BMGWASDKBNKGEI-UHFFFAOYSA-N 0.000 claims 1
- ARTHAKPKOZXFDW-UHFFFAOYSA-N tert-butyl 4-[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OC3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 ARTHAKPKOZXFDW-UHFFFAOYSA-N 0.000 claims 1
- PQLNOAQQIXKLPQ-UHFFFAOYSA-N tert-butyl 4-[[2-(1,1,2,2,2-pentafluoroethyl)-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenyl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F PQLNOAQQIXKLPQ-UHFFFAOYSA-N 0.000 claims 1
- RCABXLXBGYKLTI-UHFFFAOYSA-N tert-butyl 4-[[3,3-dimethyl-6-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-2h-indol-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)C1 RCABXLXBGYKLTI-UHFFFAOYSA-N 0.000 claims 1
- IJDAUEQFCBFCJH-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 IJDAUEQFCBFCJH-UHFFFAOYSA-N 0.000 claims 1
- XPZARCJXYPVIBV-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 XPZARCJXYPVIBV-UHFFFAOYSA-N 0.000 claims 1
- XVOGDGCWXZWQJV-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(CN3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 XVOGDGCWXZWQJV-UHFFFAOYSA-N 0.000 claims 1
- SYWDCMDDPUTUHL-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(CC3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 SYWDCMDDPUTUHL-UHFFFAOYSA-N 0.000 claims 1
- NOXPICRGCBJOJI-UHFFFAOYSA-N tert-butyl 4-[[6-[[2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=C4CCOC4=CC=3)=CC=C2C(C)(C)C1 NOXPICRGCBJOJI-UHFFFAOYSA-N 0.000 claims 1
- ASGMDOZDZHAXQM-UHFFFAOYSA-N tert-butyl 4-[[6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3CC3CCN(CC3)C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 ASGMDOZDZHAXQM-UHFFFAOYSA-N 0.000 claims 1
- DKRURERGEKGKFC-UHFFFAOYSA-N tert-butyl 6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indole-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 DKRURERGEKGKFC-UHFFFAOYSA-N 0.000 claims 1
- SWSBOEBCLSTVII-UHFFFAOYSA-N tert-butyl n-[2-[4-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenyl]ethyl]carbamate Chemical compound C1=CC(CCNC(=O)OC(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 SWSBOEBCLSTVII-UHFFFAOYSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26133901P | 2001-01-12 | 2001-01-12 | |
| US32376401P | 2001-09-19 | 2001-09-19 | |
| US10/046,681 US6995162B2 (en) | 2001-01-12 | 2002-01-10 | Substituted alkylamine derivatives and methods of use |
| PCT/US2002/000743 WO2002066470A1 (en) | 2001-01-12 | 2002-01-11 | Substituted alkylamine derivatives and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097317A Division JP2009286777A (ja) | 2001-01-12 | 2009-04-13 | 置換アルキルアミン誘導体およびそれの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004531484A JP2004531484A (ja) | 2004-10-14 |
| JP2004531484A5 true JP2004531484A5 (OSRAM) | 2005-12-22 |
| JP4408627B2 JP4408627B2 (ja) | 2010-02-03 |
Family
ID=27366957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565984A Expired - Fee Related JP4408627B2 (ja) | 2001-01-12 | 2002-01-11 | 置換アルキルアミン誘導体およびそれの使用方法 |
| JP2009097317A Pending JP2009286777A (ja) | 2001-01-12 | 2009-04-13 | 置換アルキルアミン誘導体およびそれの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097317A Pending JP2009286777A (ja) | 2001-01-12 | 2009-04-13 | 置換アルキルアミン誘導体およびそれの使用方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US6995162B2 (OSRAM) |
| EP (4) | EP2311808A1 (OSRAM) |
| JP (2) | JP4408627B2 (OSRAM) |
| KR (1) | KR100848429B1 (OSRAM) |
| CN (1) | CN1313464C (OSRAM) |
| AT (1) | ATE361288T1 (OSRAM) |
| AU (2) | AU2002248340C8 (OSRAM) |
| BG (1) | BG66160B1 (OSRAM) |
| BR (1) | BR0206435A (OSRAM) |
| CA (1) | CA2434277C (OSRAM) |
| CY (1) | CY1106748T1 (OSRAM) |
| CZ (1) | CZ303356B6 (OSRAM) |
| DE (1) | DE60219887T2 (OSRAM) |
| DK (1) | DK1358184T3 (OSRAM) |
| EA (1) | EA006973B1 (OSRAM) |
| EE (1) | EE05290B1 (OSRAM) |
| ES (1) | ES2284849T3 (OSRAM) |
| GE (1) | GEP20053692B (OSRAM) |
| HU (1) | HUP0302598A2 (OSRAM) |
| IL (4) | IL156751A0 (OSRAM) |
| IS (1) | IS2623B (OSRAM) |
| MX (1) | MXPA03006179A (OSRAM) |
| NO (1) | NO329306B1 (OSRAM) |
| NZ (1) | NZ526868A (OSRAM) |
| PL (1) | PL368209A1 (OSRAM) |
| PT (1) | PT1358184E (OSRAM) |
| RS (1) | RS51477B (OSRAM) |
| SI (1) | SI1358184T1 (OSRAM) |
| SK (1) | SK287860B6 (OSRAM) |
| UA (1) | UA77167C2 (OSRAM) |
| WO (1) | WO2002066470A1 (OSRAM) |
Families Citing this family (310)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| JP4901102B2 (ja) * | 2002-05-03 | 2012-03-21 | エクセリクシス, インク. | プロテインキナーゼモジュレーターおよびその使用方法 |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| MXPA04012948A (es) * | 2002-07-31 | 2005-09-12 | Schering Ag | Inhibidores antranilamidopiridinas vegfr-2 y vegfr-3. |
| DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
| GB0224316D0 (en) * | 2002-10-18 | 2002-11-27 | Syngenta Participations Ag | Chemical compounds |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
| TWI299664B (en) * | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| EP2527326B1 (en) | 2003-03-07 | 2014-10-08 | Santen Pharmaceutical Co., Ltd | Novel compounds having 4-pyridylalkylthio group as substituent |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| US7978887B2 (en) | 2003-06-17 | 2011-07-12 | Brown University | Methods and apparatus for identifying subject matter in view data |
| WO2005001081A1 (en) | 2003-06-27 | 2005-01-06 | UNIVERSITé LAVAL | Method of isolating cells from umbilical cord |
| RS53476B (sr) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Sredstva za specifično vezivanje faktora rasta hepatocita |
| CA2532965C (en) * | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| BRPI0412805A (pt) * | 2003-07-23 | 2006-09-26 | Synta Pharmaceuticals Corp | método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio |
| ES2222832B1 (es) | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| BRPI0414604A (pt) * | 2003-09-23 | 2006-11-07 | Novartis Ag | combinações de um inibiddor do receptor de vegf com outros agentes terapêuticos |
| MXPA06003163A (es) * | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| KR101179840B1 (ko) | 2004-02-17 | 2012-09-04 | 산텐 세이야꾸 가부시키가이샤 | 치환 또는 무치환 아미노기를 도입한 4-피리딜알킬티오기를갖는 신규 고리형 화합물 |
| CA2561791A1 (en) * | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds |
| DE102004039876A1 (de) * | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| JP2008506761A (ja) * | 2004-07-22 | 2008-03-06 | アステックス、セラピューティックス、リミテッド | プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体 |
| AU2005287057A1 (en) * | 2004-09-17 | 2006-03-30 | Osi Pharmaceuticals, Inc. | (spirocyclylamido) aminothiophene compounds as c-Kit proto- oncogene inhibitors |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| EP1844044B1 (en) | 2005-01-14 | 2010-07-21 | F.Hoffmann-La Roche Ag | Thiazole-4-carboxamide derivatives as mglur5 antagonists |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| KR101346886B1 (ko) * | 2005-01-21 | 2014-01-02 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| KR101345002B1 (ko) * | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| US20090023753A1 (en) * | 2005-03-04 | 2009-01-22 | Bayer Healthcare Ag | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| ES2548729T3 (es) | 2005-03-31 | 2015-10-20 | Santen Pharmaceutical Co., Ltd. | Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio |
| JP4834441B2 (ja) * | 2005-03-31 | 2011-12-14 | 参天製薬株式会社 | ピリミジニルアルキルチオ基を有する新規環式化合物 |
| US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| EP1787981A1 (en) * | 2005-11-22 | 2007-05-23 | Bayer CropScience S.A. | New N-phenethylcarboxamide derivatives |
| WO2007062459A1 (en) * | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| US20080108664A1 (en) * | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| JP2009526050A (ja) * | 2006-02-10 | 2009-07-16 | アムジエン・インコーポレーテツド | Amg706の水和物形態 |
| KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
| AU2007256931B2 (en) | 2006-05-30 | 2013-01-24 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
| EP2030971B1 (en) * | 2006-06-20 | 2011-10-12 | Ishihara Sangyo Kaisha, Ltd. | Pest control agent containing novel pyridyl-methanamine derivative or salt thereof |
| WO2008002816A1 (en) * | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Substituted benzamide modulators of the histamine h3 receptor |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| CN101573345A (zh) * | 2006-10-31 | 2009-11-04 | 先灵公司 | 作为蛋白激酶抑制剂的2-氨基噻唑-4-甲酰胺 |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| CN101616908B (zh) * | 2006-12-29 | 2014-09-10 | Abbvie德国有限责任两合公司 | 羧酰胺化合物及它们作为钙蛋白酶抑制剂的用途 |
| EP2118069B1 (en) | 2007-01-09 | 2014-01-01 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| TWI595005B (zh) | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類c-fms抗原結合蛋白質 |
| RU2010118481A (ru) | 2007-10-11 | 2011-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов |
| MX2010003865A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| NZ584475A (en) * | 2007-10-11 | 2012-07-27 | Vertex Pharma | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| JP5374377B2 (ja) | 2007-10-18 | 2013-12-25 | 武田薬品工業株式会社 | 複素環化合物 |
| MX2010005488A (es) | 2007-11-20 | 2010-06-01 | Janssen Pharmaceutica Nv | Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina. |
| EP2291187B1 (en) * | 2008-04-24 | 2018-08-15 | Newlink Genetics Corporation | Ido inhibitors |
| PA8840701A1 (es) | 2008-08-27 | 2010-04-21 | Leo Pharma As | NUEVO RECEPTOR VEGF-2 e INHIBIDORES DE PROTEÍNAS TIROSINA QUINASA Y SU USO FARMACÉUTICO DE LOS MISMOS |
| WO2010041218A2 (en) | 2008-10-10 | 2010-04-15 | Actelion Pharmaceuticals Ltd | Oxazolidinyl antibiotics |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2497822C2 (ru) * | 2008-12-05 | 2013-11-10 | Эббви Инк. | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| WO2010071828A2 (en) | 2008-12-19 | 2010-06-24 | Amgen Inc. | Improved method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| KR20120006545A (ko) | 2009-04-16 | 2012-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 당뇨병의 예방 또는 치료에 특히 유용한 n―아실―n’―페닐피페라진의 유도체 |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UY32668A (es) | 2009-05-26 | 2010-12-31 | Abbott Lab | Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| HRP20140621T1 (hr) * | 2009-08-24 | 2014-11-21 | Neuralstem, Inc. | Sinteza neurostimulativnog piperazina |
| PH12012501153A1 (en) * | 2009-12-08 | 2012-10-22 | Boehringer Ingelheim Int | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| CN103391773A (zh) | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US8946224B2 (en) | 2010-11-11 | 2015-02-03 | Redx Pharma Limited | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions |
| EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| NZ708508A (en) | 2010-11-23 | 2016-06-24 | Abbvie Bahamas Ltd | Methods of treatment using selective bcl-2 inhibitors |
| JP6141188B2 (ja) | 2010-11-23 | 2017-06-07 | アッヴィ・インコーポレイテッド | アポトーシス誘導剤の塩および結晶の形態 |
| CN103261186A (zh) | 2010-12-13 | 2013-08-21 | 诺瓦提斯公司 | 二聚化iap抑制剂 |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| US8865741B2 (en) | 2011-02-18 | 2014-10-21 | Asana Biosciences, Llc | Aminoindane compounds and use thereof in treating pain |
| MY161199A (en) | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| CN103561761A (zh) | 2011-03-23 | 2014-02-05 | 加利福尼亚大学董事会 | 用于使用抗-整合素改善抗血管生成疗法的方法和组合物 |
| US9309212B2 (en) * | 2011-05-24 | 2016-04-12 | The Wistar Institute | Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1 |
| US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
| KR101412794B1 (ko) * | 2011-07-27 | 2014-07-01 | 보령제약 주식회사 | 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体idhの阻害剤としての3−ピリミジン−4−イル−オキサゾリジン−2−オン類 |
| WO2013084138A1 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Cyclic urea derivatives as androgen receptor antagonists |
| BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
| CN102603729A (zh) * | 2012-01-12 | 2012-07-25 | 贵州大学 | N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物 |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| JP6243918B2 (ja) | 2012-10-16 | 2017-12-06 | トレロ ファーマシューティカルズ, インコーポレイテッド | Pkm2調節因子およびそれらの使用方法 |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
| DK2958907T3 (en) | 2013-02-19 | 2018-06-06 | Novartis Ag | Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| HK1213251A1 (zh) | 2013-03-14 | 2016-06-30 | Novartis Ag | 作为突变idh抑制剂的3-嘧啶-4-基-恶唑烷-2-酮化合物 |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| DK2970205T3 (da) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CA2940237C (en) | 2014-02-21 | 2023-03-07 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| CA2957548A1 (en) | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| EA201790737A1 (ru) | 2014-10-03 | 2017-08-31 | Новартис Аг | Комбинированная терапия |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| MX389663B (es) | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| EP3242934B1 (en) | 2015-01-08 | 2021-08-18 | The Board of Trustees of the Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| JP6800872B2 (ja) | 2015-03-06 | 2020-12-16 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤とその使用 |
| EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| RU2017134379A (ru) | 2015-03-25 | 2019-04-03 | Новартис Аг | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| CN112625028B (zh) | 2015-06-19 | 2024-10-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| US10577362B2 (en) | 2016-05-04 | 2020-03-03 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CN106565599A (zh) * | 2016-06-20 | 2017-04-19 | 中国药科大学 | 2‑氨甲基吡啶基烟酰胺类化合物及其制备方法和应用 |
| US11365252B2 (en) | 2016-07-20 | 2022-06-21 | University Of Utah Research Foundation | CD229 CAR T cells and methods of use thereof |
| AU2017324445A1 (en) | 2016-09-07 | 2019-04-11 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| JP7097874B2 (ja) | 2016-09-07 | 2022-07-08 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤の使用 |
| US20200055917A1 (en) | 2016-09-27 | 2020-02-20 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EP3558955B1 (en) | 2016-12-22 | 2021-08-11 | Amgen Inc. | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
| US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3641812A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| TWI851542B (zh) | 2017-09-11 | 2024-08-11 | 美商克魯松藥物公司 | Shp2之八氫環戊烷并[c]吡咯別構抑制劑 |
| FI3688032T3 (fi) | 2017-09-26 | 2025-12-09 | Cero Therapeutics Holdings Inc | Kimeerisiä nielaisureseptorimolekyylejä ja käyttömenetelmiä |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN112041307B (zh) | 2018-02-06 | 2024-02-09 | 伊利诺伊大学评议会 | 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物 |
| AU2019238326B2 (en) * | 2018-03-23 | 2025-03-06 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| WO2019191339A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof |
| AU2019243154A1 (en) | 2018-03-28 | 2020-10-01 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| WO2019195753A1 (en) | 2018-04-05 | 2019-10-10 | Tolero Pharmaceuticals, Inc. | Axl kinase inhibitors and use of the same |
| AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| ES2995514T3 (en) | 2018-05-04 | 2025-02-10 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| MX2020011907A (es) | 2018-05-10 | 2021-01-29 | Amgen Inc | Inhibidores de kras g12c para el tratamiento de cancer. |
| JOP20200303A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
| ES2938987T3 (es) | 2018-06-01 | 2023-04-18 | Amgen Inc | Inhibidores de KRAS G12c y métodos de uso de los mismos |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| CA3100390A1 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| PT3826686T (pt) | 2018-07-25 | 2025-08-04 | Advanced Accelerator Applications S A | Soluções estáveis de complexo de radionuclídeo concentrado |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
| AU2019344897B2 (en) | 2018-09-18 | 2024-01-18 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors |
| JP7358484B2 (ja) | 2018-09-25 | 2023-10-10 | アドヴァンスド・アクセラレーター・アプリケーションズ・(イタリー)・エッセエッレエッレ | 併用療法 |
| CN113382986A (zh) | 2018-09-25 | 2021-09-10 | 黑钻治疗公司 | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 |
| JP2022502496A (ja) | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス,インコーポレイティド | チロシンキナーゼ阻害剤組成物、作製方法、および使用方法 |
| CA3113379A1 (en) | 2018-09-29 | 2020-04-02 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP7676308B2 (ja) | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
| MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| CA3123871A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| KR20220007845A (ko) | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| KR20220002899A (ko) | 2019-04-19 | 2022-01-07 | 얀센 바이오테크 인코포레이티드 | 항-psma/cd3 항체로 전립선암을 치료하는 방법 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| PH12021552922A1 (en) | 2019-05-21 | 2022-04-04 | Amgen Inc | Solid state forms |
| US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| JP7640521B2 (ja) | 2019-08-02 | 2025-03-05 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
| MX2022001295A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
| AU2020324406A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| JP7756070B2 (ja) | 2019-08-02 | 2025-10-17 | アムジエン・インコーポレーテツド | Kif18a阻害剤としてのピリジン誘導体 |
| CN114787150A (zh) | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| AU2020369569A1 (en) | 2019-10-24 | 2022-04-14 | Amgen Inc. | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091960A1 (en) | 2019-11-05 | 2021-05-14 | Jounce Therapeutics, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
| US12466825B2 (en) | 2019-11-14 | 2025-11-11 | Amgen Inc. | Synthesis of KRAS G12C inhibitor compound |
| AU2020393174A1 (en) * | 2019-11-25 | 2022-06-30 | Gt Gain Therapeutics Sa | Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| MX2022008305A (es) | 2020-01-07 | 2022-08-08 | Revolution Medicines Inc | Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer. |
| AU2021219370A1 (en) * | 2020-02-12 | 2022-08-25 | Curadev Pharma Pvt. Ltd. | Small molecule STING antagonists |
| WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
| TW202214253A (zh) | 2020-06-18 | 2022-04-16 | 美商銳新醫藥公司 | 延遲、預防及治療對ras抑制劑之後天抗性之方法 |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
| CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
| WO2022140472A1 (en) | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
| CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| AU2022214491A1 (en) | 2021-01-28 | 2023-09-14 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
| WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
| AU2022227021A1 (en) | 2021-02-26 | 2023-09-21 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| US20240299371A1 (en) * | 2021-03-15 | 2024-09-12 | Board Of Regents, The University Of Texas System | Biaryl amide and heteroaryl amides for treatment of candida albicans infection |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| EP4323349A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
| EP4323350A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone compounds |
| MX2023013085A (es) | 2021-05-05 | 2023-11-16 | Revolution Medicines Inc | Inhibidores de ras. |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| JP2024529474A (ja) | 2021-07-28 | 2024-08-06 | セロ・セラピューティクス・インコーポレイテッド | キメラTim4受容体およびその使用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20240115979A (ko) | 2021-11-08 | 2024-07-26 | 프로젠토스 테라퓨틱스, 인크. | 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도 |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| JP2025509217A (ja) | 2022-03-07 | 2025-04-11 | アムジエン・インコーポレーテツド | 4-メチル-2-プロパン-2-イル-ピリジン-3-カルボニトリルを調製するための方法 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| US12331026B2 (en) | 2022-03-28 | 2025-06-17 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
| CN120504682A (zh) | 2022-06-10 | 2025-08-19 | 锐新医药公司 | 大环ras抑制剂 |
| IL320217A (en) | 2022-10-14 | 2025-06-01 | Black Diamond Therapeutics Inc | Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives |
| AU2023375457A1 (en) | 2022-11-11 | 2025-05-01 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024253668A1 (en) | 2023-04-07 | 2025-11-13 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ras相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025072462A1 (en) | 2023-09-27 | 2025-04-03 | Nikang Therapeutics, Inc. | Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202527955A (zh) | 2023-11-27 | 2025-07-16 | 美商尼坎醫療公司 | 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶2和週期蛋白依賴性激酶4的含有2,5-取代的嘧啶衍生物的雙功能化合物 |
| WO2025117981A1 (en) | 2023-12-02 | 2025-06-05 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025212828A1 (en) | 2024-04-03 | 2025-10-09 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway |
| WO2025240536A1 (en) | 2024-05-15 | 2025-11-20 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR216E (fr) * | 1901-03-19 | 1902-11-21 | Compin | Système d'appareil incinérateur pour . manchons à incan-descence |
| CH438343A (de) | 1962-11-08 | 1967-06-30 | Thomae Gmbh Dr K | Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen |
| US3226394A (en) | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
| US3291797A (en) | 1965-10-23 | 1966-12-13 | American Home Prod | 3, 4-dihydro-2h-pyran-2-ylmethyl pteridine derivatives |
| US3822277A (en) | 1967-11-13 | 1974-07-02 | C Dufour | Certain pyridyl cyclopropylamides |
| BE794226A (fr) | 1972-01-21 | 1973-07-18 | Synthelabo | Derives de la quinoleine, leur preparation et les medicaments qui en contiennent |
| DE2934543A1 (de) | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| DE3305755A1 (de) | 1983-02-19 | 1984-08-23 | Gödecke AG, 1000 Berlin | N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems |
| DE3642315A1 (de) | 1986-12-11 | 1988-06-23 | Boehringer Mannheim Gmbh | Neue pyrrolobenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
| EP0393529B1 (en) | 1989-04-20 | 1993-06-30 | Boehringer Ingelheim Pharmaceuticals Inc. | 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e][1,4]diazepin-6-ones and their use in the prevention or treatment of AIDS |
| EP0410148B1 (en) | 1989-06-28 | 1994-04-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Novel 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and thiones and their use in the prevention or treatment of AIDS |
| CA2030056C (en) | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
| US5571912A (en) | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
| EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| US5559135A (en) | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| US5532358A (en) | 1994-10-12 | 1996-07-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones |
| US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
| US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US5674876A (en) * | 1995-01-20 | 1997-10-07 | Research Development Foundation | ρ-heteroatom-substituted phenols and uses thereof |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5663357A (en) | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| RU2196137C2 (ru) | 1996-08-08 | 2003-01-10 | Зенека Лимитед | Производные хиназолина и их применение в качестве ингибиторов фактора роста эндотелия сосудов |
| US6008234A (en) | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| DE19648793A1 (de) | 1996-11-26 | 1998-05-28 | Basf Ag | Neue Benzamide und deren Anwendung |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| WO1998045268A1 (en) | 1997-04-04 | 1998-10-15 | Pfizer Products Inc. | Nicotinamide derivatives |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| JP2002512633A (ja) | 1997-06-26 | 2002-04-23 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
| CA2294240A1 (en) | 1997-06-26 | 1999-01-07 | Trelia Joyce Craft | Antithrombotic agents |
| EP1007037A4 (en) | 1997-06-26 | 2004-10-06 | Lilly Co Eli | ANTITHROMBOTIC AGENTS |
| EP0999834B1 (en) | 1997-06-26 | 2005-10-12 | Eli Lilly And Company | Antithrombotic agents |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| CN1143855C (zh) | 1997-12-19 | 2004-03-31 | 舍林公开股份有限公司 | 作为抗凝剂的邻氨基苯甲酰胺衍生物 |
| US6271237B1 (en) | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| ES2325140T3 (es) | 1998-04-20 | 2009-08-26 | ABBOTT GMBH & CO. KG | Amidas sustituidas con heterociclos como inhibidores de la calpaina. |
| US6506747B1 (en) * | 1998-06-05 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| WO2000002851A1 (en) | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| AU1023300A (en) * | 1998-11-06 | 2000-05-29 | London Health Sciences Centre | A multi-channel data acquisition system for the real-time spatial, temporal monitoring and classification of high frequency bandwidth neuronal activity |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| ATE240316T1 (de) | 1998-12-23 | 2003-05-15 | Lilly Co Eli | Heteroaromatische amide als inhibitoren von faktor xa |
| ES2263294T3 (es) | 1998-12-23 | 2006-12-01 | Eli Lilly And Company | Amidas antitromboticas. |
| US6689780B1 (en) * | 1998-12-23 | 2004-02-10 | Eli Lilly And Company | Heteroroaromatic amides as inhibitor of factor Xa |
| CA2361149A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Aromatic amides |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| JP2000256358A (ja) | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| CA2383466C (en) | 1999-09-16 | 2009-08-25 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogen-containing 6-membered cyclic compounds |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| AUPQ365299A0 (en) | 1999-10-25 | 1999-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives |
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| JP2003520854A (ja) | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
| DE10005875B4 (de) * | 2000-02-10 | 2004-05-13 | Koenig & Bauer Ag | Farbzufuhreinrichtung |
| US6509755B2 (en) | 2000-02-29 | 2003-01-21 | Schlumberger Technology Corporation | Method and device for active impedance matching |
| DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| DE10023485A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
| DE10023492A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| DE10060809A1 (de) | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7241785B2 (en) | 2001-03-23 | 2007-07-10 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic alkanoic acid derivative |
| US7312235B2 (en) | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| PL364478A1 (en) | 2001-05-08 | 2004-12-13 | Schering Aktiengesellschaft | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| WO2003000678A1 (de) | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
| US7459470B2 (en) | 2001-05-08 | 2008-12-02 | Schering Ag | N-oxide anthranylamide derivatives and their use as medicaments |
| OA12768A (en) | 2002-02-11 | 2006-07-04 | Pfizer | Nicotinamide derivatives useful as PDE4 inhibitors. |
| GB0203193D0 (en) | 2002-02-11 | 2002-03-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US7517894B2 (en) | 2002-07-31 | 2009-04-14 | Bayer Schering Pharma Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2002
- 2002-01-10 US US10/046,681 patent/US6995162B2/en not_active Expired - Lifetime
- 2002-01-11 DK DK02717325T patent/DK1358184T3/da active
- 2002-01-11 PT PT02717325T patent/PT1358184E/pt unknown
- 2002-01-11 RS YUP-605/03A patent/RS51477B/sr unknown
- 2002-01-11 AU AU2002248340A patent/AU2002248340C8/en not_active Ceased
- 2002-01-11 PL PL02368209A patent/PL368209A1/xx unknown
- 2002-01-11 MX MXPA03006179A patent/MXPA03006179A/es active IP Right Grant
- 2002-01-11 DE DE60219887T patent/DE60219887T2/de not_active Expired - Lifetime
- 2002-01-11 JP JP2002565984A patent/JP4408627B2/ja not_active Expired - Fee Related
- 2002-01-11 WO PCT/US2002/000743 patent/WO2002066470A1/en not_active Ceased
- 2002-01-11 EP EP10176822A patent/EP2311808A1/en not_active Withdrawn
- 2002-01-11 IL IL15675102A patent/IL156751A0/xx unknown
- 2002-01-11 EP EP10176821A patent/EP2311829A1/en not_active Withdrawn
- 2002-01-11 ES ES02717325T patent/ES2284849T3/es not_active Expired - Lifetime
- 2002-01-11 EP EP02717325A patent/EP1358184B1/en not_active Expired - Lifetime
- 2002-01-11 NZ NZ526868A patent/NZ526868A/xx not_active IP Right Cessation
- 2002-01-11 HU HU0302598A patent/HUP0302598A2/hu not_active IP Right Cessation
- 2002-01-11 EE EEP200300324A patent/EE05290B1/xx not_active IP Right Cessation
- 2002-01-11 EP EP07003413A patent/EP1798230A1/en not_active Withdrawn
- 2002-01-11 SI SI200230554T patent/SI1358184T1/sl unknown
- 2002-01-11 BR BR0206435-9A patent/BR0206435A/pt active Search and Examination
- 2002-01-11 CN CNB028062027A patent/CN1313464C/zh not_active Expired - Fee Related
- 2002-01-11 GE GE5315A patent/GEP20053692B/en unknown
- 2002-01-11 AT AT02717325T patent/ATE361288T1/de active
- 2002-01-11 SK SK858-2003A patent/SK287860B6/sk not_active IP Right Cessation
- 2002-01-11 CA CA002434277A patent/CA2434277C/en not_active Expired - Fee Related
- 2002-01-11 EA EA200300788A patent/EA006973B1/ru not_active IP Right Cessation
- 2002-01-11 KR KR1020037009274A patent/KR100848429B1/ko not_active Expired - Fee Related
- 2002-01-11 CZ CZ20031863A patent/CZ303356B6/cs not_active IP Right Cessation
- 2002-11-01 UA UA2003087598A patent/UA77167C2/uk unknown
-
2003
- 2003-07-02 IL IL156751A patent/IL156751A/en not_active IP Right Cessation
- 2003-07-03 IS IS6865A patent/IS2623B/is unknown
- 2003-07-11 NO NO20033181A patent/NO329306B1/no not_active IP Right Cessation
- 2003-07-21 BG BG108012A patent/BG66160B1/bg unknown
-
2005
- 2005-09-23 US US11/234,713 patent/US8058445B2/en not_active Expired - Lifetime
-
2006
- 2006-02-01 AU AU2006200437A patent/AU2006200437B2/en not_active Ceased
-
2007
- 2007-07-20 CY CY20071100969T patent/CY1106748T1/el unknown
-
2008
- 2008-09-01 IL IL193813A patent/IL193813A0/en not_active IP Right Cessation
- 2008-09-01 IL IL193814A patent/IL193814A/en not_active IP Right Cessation
-
2009
- 2009-04-13 JP JP2009097317A patent/JP2009286777A/ja active Pending
-
2011
- 2011-11-15 US US13/297,213 patent/US8642624B2/en not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/829,288 patent/US20130273004A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004531484A5 (OSRAM) | ||
| JP2004527499A5 (OSRAM) | ||
| CA2434178A1 (en) | Substituted amine derivatives and methods of use | |
| JP2006502112A5 (OSRAM) | ||
| JP2004531473A5 (OSRAM) | ||
| AU2003252011B2 (en) | Substituted 2-alkylamine nicotinic amide derivatives and use there of | |
| JP2007504148A5 (OSRAM) | ||
| JP2009519967A5 (OSRAM) | ||
| CN101959516B (zh) | 用以治疗癌症的包含喹喔啉PI3Kα抑制剂的组合治疗 | |
| ES2261476T3 (es) | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. | |
| JP2006520805A5 (OSRAM) | ||
| RU2005136429A (ru) | Производные азаспироалканов в качестве тнгибиторов металлопротеаз | |
| JP2010513444A5 (OSRAM) | ||
| BG108012A (bg) | Заместени алкиламинови производни и методи за използването им | |
| JP2020512343A5 (OSRAM) | ||
| JP2010529991A5 (OSRAM) | ||
| ES2361933T3 (es) | Uso de derivados de azabiciclo hexano. | |
| RU2004112191A (ru) | Лактамсодержащие соединения и их производные в качестве ингибиторов фактора ха | |
| JP2007503450A5 (OSRAM) | ||
| JP2010513304A5 (OSRAM) | ||
| RU2008141761A (ru) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ | |
| RU2003116649A (ru) | Гетероциклилэфирзамещенные имидазохинолины | |
| CA3051327A1 (en) | Multisubstituted aromatic compounds as serine protease inhibitors | |
| JP2008525502A5 (OSRAM) | ||
| JP2021501145A5 (OSRAM) |